Financings Neutral

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners Closes $600K Lifeline as Stock Tests 52-Week Lows Amid Dilution and Trial Rollout

By The Northwire Desk — AI Analysis Mar 30, 2026 · 06:03 ARCH · 0.55 Arch Biopartners Inc.

Executive Summary

Arch Biopartners closed a non-brokered private placement of 1,000,000 common shares at CAD $0.60 per share, generating gross proceeds of CAD $600,000.
The closing follows the March 30, 2026 announcement of the same terms, making this a purely administrative follow-through.
Proceeds are allocated to general working capital and operating expenses not covered by existing human-trial funding grants.
81,667 shares were issued to a company officer as a related-party transaction, exempt from formal MI 61-101 valuation and minority approval thresholds.
All issued shares carry a standard four-month-plus-one-day statutory hold period.
Post-offering, the company reports 67,933,289 common shares outstanding.

Material Impact

The news is entirely expected and contains zero new fundamental or clinical information. The market had three days to price in the dilution and cash injection.
The raise size ($600,000) is immaterial relative to the capital requirements of running multiple Phase II trials across nine international sites. It provides only a short-term liquidity patch rather than a strategic runway extension.
Pricing at $0.60 represents a 42% discount to the November 2025 private placement price of $1.04, highlighting deteriorating market sentiment and a lack of external institutional demand.
The transaction does not alter the clinical development timeline, trial design, or fundamental risk profile of the LSALT peptide or PONTiAK programs.

ARCH · Price

Company Overview

Arch Biopartners is a clinical-stage biopharmaceutical company focused on developing novel therapies for acute kidney injury (AKI) and chronic kidney disease (CKD).
Flagship Project: LSALT peptide, a first-in-class DPEP1 inhibitor targeting inflammation-mediated organ injury. It is currently in a Phase II, randomized, double-blind, placebo-controlled trial for cardiac surgery-associated AKI (CS-AKI).
Trial Design: Target enrollment of 240 patients across nine global sites. Primary endpoint is the percentage of subjects developing AKI within seven days post on-pump cardiac surgery per KDIGO criteria.
Secondary Pipeline: PONTiAK (cilastatin) in Phase II for toxin-induced AKI (698-patient target across Alberta sites, with U.S. expansion planned). Preclinical CKD platform targeting IL-32 acquired via Lipdro Therapeutics.

More from Arch Biopartners Inc.